160 completed, 41 terminated, 32 unknown, 12 recruiting. 138 Phase 2, 72 Phase 1, 64 Phase 3, 10 Phase 4, 7 Not applicable.
Follow Mitoxantrone: new trials by email Literature Review of Mitoxantrone trials Research Report on Mitoxantrone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery mitoxantrone hydrochloride injection - Papillary Thyroid Cancer | Phase 4 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 114 | 2026-02-01 | 2026-01-21 |
| BCL2i CLAG-M in R/R Acute Myeloid Leukemia Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 52 | 2024-11-26 | 2026-04-01 |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level 1 - Relapsed Adult AML, Refractory AML | Phase 1 | Withdrawn | Medical College of Wisconsin | 2024-08-31 | 2024-08-13 | |
| Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML Chidamide, Venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 240 | 2024-08-21 | 2025-11-17 |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia Venetoclax, Azacitidine, Mitoxantrone - Leukemia, Myeloid Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 30 | 2024-07-21 | 2026-01-15 |
| MRD-positive AML Clinical Study Ivosidenib, Gilteritinib, Venetoclax - AML, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 537 | 2024-05-11 | 2026-08-10 |
| Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia Ivosidenib, Venetoclax, Gilteritinib - AML, Refractory | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 458 | 2024-02-22 | 2026-08-07 |
| CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients Quizartinib, Etoposide, Dexrazoxane - Acute Myeloid Leukemia in Children | Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 60 | 2024-02-06 | 2025-08-05 |
| Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer Technetium Tc 99m Sulfur Colloid Injection, Mitoxantrone Hydrochloride Injection for Tracing - Sentinel Nodes, Breast Cancer | Phase 3 | Completed | HTA Co., Ltd. | 213 | 2024-01-02 | 2026-08-14 |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Venetoclax, Azacitidine, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 70 | 2023-07-25 | 2026-09-17 |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Ayman H Qasrawi | 2023-03-01 | 2023-04-25 | |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-11-06 |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children Cladribine, G-CSF, Cytarabine - Leukemia, Monocytic, Acute, Pediatric AML | Phase 2 / Phase 3 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 43 | 2021-12-01 | 2023-07-27 |
| Study of Magrolimab Combinations in Participants With Myeloid Malignancies Magrolimab, Azacitidine, Venetoclax - Myeloid Malignancies | Phase 2 | Terminated | Gilead Sciences | 54 | 2021-06-28 | 2025-03-20 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine - Acute Myeloid Leukemia, Myeloid Neoplasm | Phase 2 | Completed | Fred Hutchinson Cancer Center | 60 | 2020-05-27 | 2026-06-29 |
| Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor - Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia | Phase 1 | Terminated | University of Washington | 13 | 2020-05-08 | 2023-12-28 |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2020-05-05 | 2026-06-11 |
Showing 20 of 262. Sign in to see all of them.
Leukemia, Myeloid, Acute (104) · Leukemia (53) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (38) · Lymphoma (29) · Prostatic Neoplasms (28) · Leukemia, Monocytic, Acute (26) · Congenital Abnormalities (23) · Leukemia, Erythroblastic, Acute (23) · Leukemia, Myelomonocytic, Acute (22) · Leukemia, Megakaryoblastic, Acute (21) · Recurrence (18) · Lymphoma, Follicular (17) · Lymphoma, Non-Hodgkin (17) · Myelodysplastic Syndromes (17) · Lymphoma, Large B-Cell, Diffuse (16)
National Cancer Institute (NCI) (15) · Fred Hutchinson Cancer Center (11) · Children's Oncology Group (8) · European Organisation for Research and Treatment of Cancer - EORTC (8) · St. Jude Children's Research Hospital (8) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (5) · University of Washington (5) · German CLL Study Group (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Masonic Cancer Center, University of Minnesota (4) · Pfizer (4) · University of Ulm (4) · Arog Pharmaceuticals, Inc. (3) · Case Comprehensive Cancer Center (3)
United States (158) · Germany (37) · France (31) · Canada (28) · Italy (27) · United Kingdom (25) · Australia (20) · Belgium (17) · Netherlands (17) · Spain (17) · China (16) · Austria (13) · Poland (12) · South Korea (11) · Czechia (10)
Roland Walter (5) · Judith Karp (4) · Sima Jeha, MD (4) · Anna Halpern (3) · Daniel J. Weisdorf, MD (3) · Nathan Fowler, MD (3) · Sergio Amadori, MD (3) · Umberto Vitolo, MD (3) · Alan K. Burnett, MD, FRCP (2) · Anjali Advani (2) · Daniel P. Petrylak, MD (2) · Dieter Hoelzer, MD, PhD (2) · Franco Mandelli, MD (2) · Leona A. Holmberg, MD, PhD (2)
PMID 36815378, PMID 37267439, PMID 38295280, PMID 42085603, PMID 34596937, PMID 40294366, PMID 42668697, PMID 10604271, PMID 11857298, PMID 12239143, PMID 12419743, PMID 12947070, PMID 15339678, PMID 15353542, PMID 15470214, PMID 15637138, PMID 15761020, PMID 16136166, PMID 16333838, PMID 16622120, PMID 16782921, PMID 16831964, PMID 16888080, PMID 16932345, PMID 17039234, PMID 17252021, PMID 17315155, PMID 17339189, PMID 17407135, PMID 17611565, PMID 18025439, PMID 18213528, PMID 18299450, PMID 18349405, PMID 18467731, PMID 18782306, PMID 18824292, PMID 19130298, PMID 19242495, PMID 19291085, PMID 19349545, PMID 1950172, PMID 19638218, PMID 19826132, PMID 20038732, PMID 20071660, PMID 20209646, PMID 20223728, PMID 20378563, PMID 20393132
P30CA015704 (7), U01CA070095 (5), U10CA180886 (5), P30CA043703 (4), 2009 (3), 2014 (3), P30CA006973 (3), U10CA032102 (3), U10CA098543 (3), 2004 (2), 2008 (2), 2015 (2), 2017 (2), P01CA075606 (2), P30CA012197 (2)